Eprodisate

DB06405InvestigationalSmall molecule

Eprodisate slows the decline of renal function in AA amyloidosis.

Mechanism: Decline in renal function associated with Amyloid A (AA) amyloidosis can be slowed by eprodisate (Kiacta), a drug that inhibits the deposit of the complex protein in tissues. AA amyloidosis is a serious, frequently fatal disorder involving deposits of amyloid fibrils in various organs and tissues. It is a complication of many chronic inflammatory disorders, but little is known about its etiology or natural history. Eprodisate delays the progression of AA amyloidosis-associated renal disease.
Curator reviewed
Primary indication: Investigated for use/treatment in amyloidosis.Curator reviewed
Formula / weight: C₃H₈O₆S₂ · 204.21 g/mol (avg)
Also known as: Propane-1,3-disulfonate · Propane-1,3-disulphonate
Code names: NC-503

Resolves to

Compound

Structure

InChIKeyMGNVWUDMMXZUDI-UHFFFAOYSA-NSMILESOS(=O)(=O)CCCS(O)(=O)=O

Targets

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eprodisate, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.